Latest News for: ets-viii

Edit

ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025

Pharmiweb 10 Mar 2025
A new phase IIb study with VH3810109 (VH109), an investigational, broadly neutralising antibody (bNAb) offers efficacy and safety findings of the bNAb (subcutaneous and IV administration) in combination with CAB LA[viii] ... [viii] Taiwo B, et al.
  • 1
×